Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
Geographic Atrophy
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
A key executive is leaving
Since May 14, 2026 · was worth 15, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 60 (final count)
- Started
- Feb 23, 2023
- Main results expected
- Feb 3, 2026
- Fully finished
- Feb 3, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events))
Measured over: 12 months (Screening to 12 months post OCU410 administration)
Change in anatomy of ocular structures using Slit Lamp Biomicroscopy
Measured over: 12 months (Screening to 12 months post OCU410 administration)
Change in anatomy of ocular structures using Indirect ophthalmoscopy
Measured over: 12 months (Screening to 12 months post OCU410 administration)
Change from baseline in BCVA (Best Corrected Visual Acuity)
Measured over: 12 months (Screening to 12 months post OCU410 administration)
Change in Low Luminance Visual Acuity
Measured over: 12 months (Screening to 12 months post OCU410 administration)
Change in the Intraocular Pressure (mmHg)
Measured over: 12 months (Screening to 12 months post OCU410 administration)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- key_exec_departure: base 15, now 2, since 2026-05-14, fades (half-life) · source filing
Raw record changes
- none yet
Trial ID NCT06018558 · record last updated 2026-10-30 · checked 2026-11-09 15:47 UTC